Cryotherapy for nodal metastasis in NSCLC with acquired resistance to immunotherapy
Abstract Novel approaches with checkpoint inhibitors in immunotherapy continue to be essential in the treatment of non-small cell lung cancer (NSCLC). However, the low rate of primary response and the development of acquired resistance during the immunotherapy limit their long-term effectiveness. Th...
Main Authors: | Lucas C. Adam, Junaid Raja, Johannes M. Ludwig, Adebowale Adeniran, Scott N. Gettinger, Hyun S. Kim |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2018-12-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s40425-018-0468-x |
Similar Items
-
Immuno-thermal ablations – boosting the anticancer immune response
by: Ryan Slovak, et al.
Published: (2017-10-01) -
Cryoablation and immunotherapy: an overview of evidence on its synergy
by: B. M. Aarts, et al.
Published: (2019-05-01) -
Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial
by: Florian Eichhorn, et al.
Published: (2019-05-01) -
Review and perspective on adjuvant and neoadjuvant immunotherapies in NSCLC
by: Yi C, et al.
Published: (2019-09-01) -
TMB in NSCLC: A Broken Dream?
by: Sara Bravaccini, et al.
Published: (2021-06-01)